- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05033743
Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A single-center prospective pilot study with once-weekly oral secnidazole granule treatment of acute condition for two-weeks followed by prophylactic treatment of asymptomatic responders with once-weekly secnidazole for 16 weeks, followed by no therapy for 12 weeks. The final follow-up evaluation is at week 28.
Eligible women with a current symptomatic bacterial vaginosis infection (> or = 3 Amsel criteria) and a history of at least 2 previous episodes of bacterial vaginosis in the past year will be enrolled in the open-label treatment study. All women will be treated with 2g of secnidazole granules orally once-weekly for 2 weeks. At the second visit, 3-5 days after completion of treatment, women who have a resolution of bacterial vaginosis (asymptomatic and < or = 2 Amsel criteria) will continue on once-weekly secnidazole for 16 weeks.
Patients will be evaluated every 4 weeks for recurrence of bacterial vaginosis. This will include questions about symptoms as well as a pelvic examination for assessment of vaginal discharge (> or = 3 Amsel criteria). We will also collect any information on other clinical evaluations for recurrence and the dates of diagnoses and types of treatments they may have received. Those who remain without recurrence during the 16-week suppressive phase will be followed for an additional 12 weeks off therapy, with assessment for recurrence at weeks 22 and 30. Throughout the study, data will be collected on participants' compliance and on the occurrence of adverse events.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Graham A Hogg
- Phone Number: 3179620415
- Email: gahogg@iu.edu
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Hospital - Coleman Center for Women
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to consent in English
- Current symptomatic bacterial vaginosis infection
- History of at least 2 previous episodes of bacterial vaginosis in the past year
Exclusion Criteria:
- Current gynecologic infection or condition, including candida vaginitis, gonorrhea, chlamydia, trichomonas, desquamative inflammatory vaginitis, atrophic vaginitis.
- Pre-existing heart conditions
- Pre-existing neurological conditions
- Currently Pregnant or breastfeeding
- Women taking anticoagulants, lithium, metoclopramide, or disulfiram therapy
- Hypersensitivity to secnidazole or other drugs in the same class.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Group
Secnidazole treatment
|
Once weekly 2g oral secnidazole for 18 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With at Least One Episode of Bacterial Vaginosis
Time Frame: 30 weeks
|
Overall failure rate as measured by the number of subjects with at least one episode of bacterial vaginosis in the 30 week follow-up period.
|
30 weeks
|
Probability of Failure at 210 Days
Time Frame: 210 days (30 weeks)
|
To assess the efficacy of secnidazole, we estimated failure rates and 95% exact confidence intervals for initial treatment, suppression therapy following initial resolution of BV symptoms, and overall.
For the time-to-failure analysis, time was defined as the number of days since the second visit where clinical resolution of initial BV was confirmed.
The non-parametric maximum likelihood estimate (NPMLE) of the survival curve was estimated using the interval package in R to account for the interval censored data.
Results are presented using an Amsel criteria score of as well as for BV diagnosis.
All analyses were conducted using R 4.2.2 (R Core Team, 2020) in RStudio (RStudio Team 2021).
|
210 days (30 weeks)
|
The Number of Subjects That Failed Treatment in the Supressive Phase
Time Frame: 30 weeks
|
The probability of recurrence or treatment failure was calculated as time from the second visit in days.
This timeframe is the suppressive therapy phase and was 30 weeks long.
|
30 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects Who Experienced Recurrence 3-5 Days After Initial Treatment (Initial Treatment Was 2 Weeks Long)
Time Frame: 3-5 days after initial treatment after initial treatment of 2 weeks
|
Recurrence was measured using the Amsel criteria.
The Amsel criteria are: 1) Homogenous white discharge, 2) pH > 4.5, 3) amine odor (whiff) test, 4) clue cells on microscopy
|
3-5 days after initial treatment after initial treatment of 2 weeks
|
Number of Subjects Who Experienced Recurrence 6 Weeks After Start of Initial Treatment
Time Frame: week 6
|
Recurrence was measured using the Amsel criteria.
The Amsel criteria are: 1) Homogenous white discharge, 2) pH > 4.5, 3) amine odor (whiff) test, 4) clue cells on microscopy
|
week 6
|
Number of Subjects Who Experienced Recurrence 10 Weeks After Start of Initial Treatment
Time Frame: week 10
|
Recurrence was measured using the Amsel criteria.
The Amsel criteria are: 1) Homogenous white discharge, 2) pH > 4.5, 3) amine odor (whiff) test, 4) clue cells on microscopy
|
week 10
|
Number of Subjects Who Experienced Recurrence 14 Weeks After Start of Initial Treatment
Time Frame: week 14
|
Recurrence was measured using the Amsel criteria.
The Amsel criteria are: 1) Homogenous white discharge, 2) pH > 4.5, 3) amine odor (whiff) test, 4) clue cells on microscopy
|
week 14
|
Number of Subjects Who Experienced Recurrence 18 Weeks After Start of Initial Treatment
Time Frame: week 18
|
Recurrence was measured using the Amsel criteria.
The Amsel criteria are: 1) Homogenous white discharge, 2) pH > 4.5, 3) amine odor (whiff) test, 4) clue cells on microscopy
|
week 18
|
Number of Subjects Who Experienced Recurrence 22 Weeks After Start of Initial Treatment
Time Frame: week 22
|
Recurrence was measured using the Amsel criteria.
The Amsel criteria are: 1) Homogenous white discharge, 2) pH > 4.5, 3) amine odor (whiff) test, 4) clue cells on microscopy
|
week 22
|
Number of Subjects Who Experienced Recurrence 30 Weeks After Start of Initial Treatment
Time Frame: week 30
|
Recurrence was measured using the Amsel criteria.
The Amsel criteria are: 1) Homogenous white discharge, 2) pH > 4.5, 3) amine odor (whiff) test, 4) clue cells on microscopy
|
week 30
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participant With Compliance
Time Frame: 18 weeks
|
Subject compliance with the study medication, based on questionnaire that asked if the participant took the medication as scheduled and asked about side effects.
|
18 weeks
|
Number of Participants With Tolerance
Time Frame: 18 weeks
|
Subject tolerance with the study medication, based on questionnaire that asked if the participant took the medication as scheduled and asked about side effects.
|
18 weeks
|
Number of Adverse Events
Time Frame: 30 weeks
|
Number of adverse events that participants experienced
|
30 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Chemen Neal, MD, Assistant professor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Disease Attributes
- Bacterial Infections
- Bacterial Infections and Mycoses
- Vaginitis
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Recurrence
- Vaginal Diseases
- Vaginosis, Bacterial
- Anti-Infective Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Secnidazole
Other Study ID Numbers
- 10283
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Bacterial Vaginosis
-
Kaiser PermanenteWithdrawnRecurrent Bacterial VaginosisUnited States
-
University of Alabama at BirminghamWayne State UniversityCompletedRecurrent Bacterial VaginosisUnited States
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
Douglas KwonRecruiting
-
Alfasigma S.p.A.ParexelTerminatedBACTERIAL VAGINOSISUnited States
-
CDA Research Group, Inc.TerminatedBacterial Vaginosis (BV)United States
-
Zagazig UniversityUnknownBacterial Vaginosis TreatmentEgypt
-
Zagazig UniversityRecruitingBacterial Vaginosis | Vaginal | MicrobiologyEgypt
-
Unity Health TorontoCompleted
-
Mount Sinai Hospital, CanadaUnity Health TorontoCompletedPregnant Women Who Test Positive for Bacterial VaginosisCanada
Clinical Trials on Secnidazole 2 GM Oral Granules
-
The Affiliated Hospital of Qingdao UniversityRecruitingCOVID-19 | Child, OnlyChina
-
China Academy of Chinese Medical SciencesRecruitingAtrial Premature ComplexesChina
-
Mayo ClinicNational Center for Advancing Translational Sciences (NCATS)Recruiting
-
Steno Diabetes Center CopenhagenZealand University Hospital; AstraZenecaUnknownType 2 Diabetes Mellitus With Kidney ComplicationsDenmark
-
Merck Sharp & Dohme LLCCompletedHCV InfectionUnited States, Germany, Poland, Sweden
-
Lianyungang Kanion Group, Ltd.Completed
-
OncBioMune PharmaceuticalsUnited States Department of DefenseUnknown
-
Dartmouth-Hitchcock Medical CenterCompletedLeukemia | Multiple Myeloma | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis)United States
-
Chiang Mai UniversityCompletedHyperuricemia | GoutThailand